Vaxcyte (formerly SutroVax) is developing best-in-class conjugate vaccines and complex antigen-based vaccines for infectious diseases. The company's lead programme is a broad-spectrum pneumococcal conjugate vaccine currently in clinical trials. Vaxcyte has an exclusive license to Sutro Biopharma’s Xpress CF™ platforms for cell free protein synthesis and site-specific conjugation.

LocationFoster City, CA
CEOGrant Pickering
Partner Kurt von Emster